UBS resumes Certara stock coverage with neutral rating, $10 target

UBS resumed coverage of Certara with a Neutral rating and $10 price target, citing limited visibility into software growth and EBITDA-margin expansion despite the stock appearing inexpensive relative to its history. Certara's Q2 2026 adjusted EPS of $0.08 missed consensus by 20%, while $93.3 million in revenue was 5.35% below expectations, as weak services performance and higher costs offset robust software growth. UBS estimates the market implies 5%-6% revenue CAGR and 15-45bps of annual EBITDA-margin expansion over 10 years, below consensus expectations for roughly 100bps of annual margin expansion from 2026-2030.

Analysis

CERT’s setup is less about end-market demand than conversion: incremental biotech funding will not translate into software revenue until customers expand modeling workflows, procurement cycles clear, and service engagements convert into recurring platform adoption. That lag makes the next 1-3 months vulnerable to another guidance reset, especially if services utilization remains weak; cost actions are unlikely to create operating leverage while product investment and stranded-cost absorption persist.

The market appears to discount only modest growth and margin improvement, limiting the case for an outright structural short at depressed levels. However, consensus embeds materially faster margin progression than the company’s current operating architecture supports, creating asymmetric downside around the next earnings report or FY guidance update. The key falsifier is software ARR/bookings acceleration sufficient to demonstrate that services weakness is cyclical rather than a customer-adoption problem, accompanied by sequential EBITDA-margin improvement rather than cost-saving promises.

A second-order beneficiary of tighter biopharma R&D budgets could be larger, more deeply embedded software vendors: customers may consolidate vendors rather than add a specialized biosimulation platform with limited internal awareness. Simulations Plus (SLP) is the cleaner relative comparison given its higher-margin software orientation; Schrödinger (SDGR) offers greater biotech-spending beta but carries materially higher platform and drug-discovery execution risk. UBS’s Neutral initiation is not independently catalytic, so the relevant event is management’s evidence of bookings, renewal, and utilization inflection rather than the rating itself.

Key Decisions for Investors

• Maintain an underweight/watch stance on CERT into the next earnings or guidance event; do not initiate a directional short solely on valuation because low embedded expectations can cap downside. Escalate to a short only if management cuts revenue expectations, services utilization deteriorates again, or EBITDA-margin guidance fails to improve sequentially.
• For a 3-6 month relative-value expression, consider long SLP / short CERT in equal dollar exposure, subject to confirming comparable valuation and borrow availability. The thesis is recurring-software margin resilience versus CERT’s execution-dependent margin bridge; exit if CERT reports sustained software-bookings acceleration and at least two quarters of sequential margin expansion.
• Use biotech funding and financing activity as a leading indicator, not a near-term CERT revenue signal: improving funding is constructive for 6-18 month demand, but only initiate a long thesis after disclosed net retention, software bookings, or renewal metrics show conversion. Absent those data, treat funding strength as narrative support rather than an earnings catalyst.
• Avoid CERT options until implied volatility, open interest, and post-earnings move history are available; the article provides no pricing data to establish whether downside puts offer positive expected value.